

Award Number: W81XWH-12-1-0596

TITLE: Examination of the mGluR-mTOR Pathway for the Identification of Potential Therapeutic Targets To Treat Fragile X

PRINCIPAL INVESTIGATOR: Thomas A. Jongens, Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, PA 19104

REPORT DATE: November 2016

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE November 2016		2. REPORT TYPE Final		3. DATES COVERED 30Sept2012 - 29Aug2016	
4. TITLE AND SUBTITLE Examination of the mGluR-mTOR Pathway for the Identification of Potential Therapeutic Targets To Treat Fragile X				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0596	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Thomas A. Jongens, Ph.D. E-Mail: jongens@mail.med.upenn.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Pennsylvania Philadelphia, PA 19104-6145				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Fragile X Syndrome (FXS) is a single gene disorder caused by loss of <i>FMR1</i> gene function. This disease leads to cognitive impairment and is the most common genetic cause of autism, accounting for 2-6% of all diagnosed cases (Hagerman et al 2008). In previous studies of a <i>Drosophila</i> model for FXS, we identified pharmacological treatments that rescued phenotypes relevant to this syndrome such as social, neuroanatomical and cognitive deficits (McBride et al., 2005; Choi et al., 2010). These results have been translated to the mouse model of FXS leading to the impetus to initiate clinical trials with Fragile X patients (Yan et al., 2005; Dolen et al., 2007; de Vrij et al., 2008; Choi et al., 2011). The fact that clinical trials of two distinct compounds identified in flies and tested in mice have reported some level of efficacy highlights the relevance of <i>Drosophila</i> and mouse-based disease modeling to identify potential treatments for developmental brain disorders and other diseases (Berry-Kravis et al., 2008; Berry-Kravis et al., 2009;					
15. SUBJECT TERMS Nothing listed					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	18	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	3
Body.....	3
Reportable Outcomes.....	7
Key Research Accomplishments.....	7
Conclusion.....	8
References.....	92
Appendices.....	

Introduction

Fragile X syndrome is the leading cause of intellectual disability resulting from a single gene mutation. Previously, we characterized social and cognitive impairments in a *Drosophila* model of Fragile X syndrome and demonstrated that these impairments were rescued by treatment with metabotropic glutamate receptor (mGluR) antagonists or lithium. In the mouse model of Fragile X a well-characterized phenotype is enhanced mGluR-dependent long-term depression (LTD) at Schaffer collateral to CA1 pyramidal synapses of the hippocampus. Last year we have reported the use of PDE-4 inhibitors in rescuing social, and memory phenotypes in the mouse as well as the enhanced-LTD phenotype observed in the *Fmr1* mouse KO. Last year we also reported the finding that metformin treatment also rescues the memory phenotype in the fly model of Fragile X. In this year we have focused on metformin treatment in the fly model and prepared to perform metformin treatment in the mouse to determine if it can also rescue memory and other phenotypes in the mouse model.

Metformin is an important drug to test in the fly and mouse models. One of the known targets of metformin is AMPK. By activating AMPK, it reduces the activity of the TORC1(mTOR) pathway (see figure 1 below) Most importantly, metformin is an FDA approved drug that has a very safe and long clinical history. It is commonly used to treat type II diabetes in humans and has recently been used to treat weight gain in patients treated with anti-psychotics. It is safe enough to prescribe to children and is now routinely prescribed to children as young as 5 years of age. If metformin is effective in the fly and mouse model, clinical trials with Fragile X patients would clearly be warranted.





Figure 1. Insulin, mTOR signaling pathway the activity of metformin. Metformin has two activities that act to reduce mTOR signaling activity. First it acts to activate AMPK which increases the activity of the TSC1/II complex and represses Rheb activity more, thus activating mTOR less. Metformin also activates the transcription of PTEN, which results in increased repression of PI3K and less activation of Akt and thus less repression of TscI/II and again adding to the repression of Rheb and thus less activation of mTOR.

To study the efficacy of metformin in more detail, we have tested the effect of treating *dfmr1* mutants during development, during adulthood or both and tested for short-term memory as well as for rescue of circadian behavior. We found that we could not rescue the circadian defect (**Fig 2**).

Effect on Circadian Behavior:



Effect on Courtship-Based Memory:




Figure 2. Effect of developmental and adulthood metformin treatment on circadian behavior and courtship-based memory. **a-b**, The circadian behavior of flies raised on **a**, 30µM or **b**, 100µM metformin and moved to 1mM metformin or vehicle control food within 24 hour of eclosion was examined. Metformin treatment did not improve the rhythmicity of *dfmr1* mutants. **c-d**, Flies raised on **c**, 30µM metformin or **d**, 100 µM metformin and moved to 1mM metformin or vehicle control food within 24 hours of eclosion were tested in the conditioned courtship paradigm. Treatment with either 30µM or 100µM metformin in development alone, or paired with 1mM metformin treatment in adulthood rescued STM in *dfmr1* mutant flies. Both MIs and CIs are displayed for each experiment. N ranged between 17-27.

Completion of metformin studies in the *Fmr1* KO mouse model of Fragile X Syndrome.

We demonstrated that metformin treatment in the mouse was well tolerated (**Fig 3**). We observed that the *Fmr1* KO mouse maintain a relatively normal weight profile with high dosage of metformin. Metformin did not affect rate of weight gain through development into adulthood.

We used two protocols for metformin administration through drinking water at a 0.3mg/ml concentration. Adulthood treatment consisted of 3 weeks of metformin administration starting at 9 weeks of age. Developmental treatment began from weaning through adulthood with a minimum of 9 weeks of metformin administration. Often patients are administered metformin for an extended period of time and thus, the developmental protocol for metformin administration more closely tracks possible therapeutic use.

To examine the effects of metformin treatment on physical phenotypes in the *Fmr1* KO mice, we dissected and measured the weights of the testes in adult mice (15+ weeks of age). Macroorchidism is a well characterized physical phenotype of FXS syndrome that is recapitulated in *Fmr1* KO mice. Administration of 0.3 mg/ml metformin *ad libitum* via drinking water for 3 weeks starting at 9 weeks of age (adulthood administration) or continuously from 3 weeks of age until adulthood (developmental administration) did not result in significant change in testes size (**Fig 4**).

We had previously established conditions to perform the rotarod test that show a clear and reproducible difference between the mutants and littermate controls. We examined the effects of metformin on rotarod performance, which measures motor learning and coordination. Treatment with metformin did not significantly affect performance in the rotarod task (**Fig 5**).

As proof of principle, we examined the abundance of phosphorylated AMPK and phosphorylated mTOR in the brains of *Fmr1* KO mice and wildtype mice after metformin administration. Interestingly, we found that metformin modulates AMPK phosphorylation (data not shown) and mTOR phosphorylation only after adulthood treatment and not developmental treatment (**Fig 6**).




Figure 3. Effect of high dose metformin on *Fmr1* KO and control mice to determine how well the drug is tolerated. We find that mice that were given a high dose of metformin (2.0mg/ml) (a comparable dose for type II diabetes patients would be 200mg/ml) maintain normal weight and do not show any obvious negative effects of metformin treatment. They were placed on metformin at 3 weeks of age.




Figure 4. Effect of developmental and adulthood metformin on macroorchidism in *Fmr1* KO mice. *Fmr1* KO mice have enlarged testes compared to WT mice. Metformin treatment did not affect testes size in *Fmr1* knockout mice with adulthood (A) or developmental (B) application at 0.3mg/ml. N is indicated by the number in the bar graphs.




Figure 5. Effect of developmental and adulthood metformin on rotarod performance in *Fmr1* KO mice. *Fmr1* KO mice and wildtype littermate controls were trained on the rotarod task over 4 days with 3 trials per day. During the first 6 trials, the rotarod accelerated from 4 rpm to 40 rpm. During the last 6 trials, the rotarod accelerated from 8 rpm to 80 rpm. Time to fall off the rotarod was measured in seconds. Metformin treatment did not affect rotarod performance in *Fmr1* knockout mice with adulthood (A) or developmental (B) application.




Figure 6. Effect of developmental and adulthood metformin on mTOR phosphorylation in the cerebellum of *Fmr1* KO mice. Cerebellum was dissected and processed to analyze mTOR phosphorylation in *Fmr1* KO mice and wildtype littermate controls. Metformin treatment at 0.3mg/ml significantly decreased mTOR phosphorylation with adulthood application (A), but not with developmental (B) application. N values ranged 4 to 7.

After extensive behavioral testing of *Fmr1* KO mice, we determined that few reported phenotypes could be reproduced in our hands. This includes marble burying, novel object recognition, object place memory, and reversal learning in the water Y maze (data not shown).

It has been previously reported that *Fmr1* KO mice are hypoactive compared to wildtype littermates. However, we have found hypoactivity in the during the dark and active period. Furthermore, there is a slight but significant hyperactivity during the light phase in *Fmr1* KO mice (Fig 7). Interestingly, preliminary data suggests that hypoactivity during the active phase can be rescued with adulthood metformin administration




Figure 7. *Fmr1* KO mice is hypoactive in the dark period. Activity of *Fmr1* KO mice were measured using infrared beam breaks over a period of 2 weeks. Compared to wildtype littermate controls, *Fmr1* KO mice were consistently hypoactive during the dark phase.

(Fig 8), but not developmental metformin administration (data not shown).




Figure 8. Effect of adulthood metformin on activity in *Fmr1* KO mice. Metformin treatment rescued the hypoactivity seen in *Fmr1* knockout mice after adulthood treatment.

Key Research Accomplishments:

Task 12c-The behavioral testing of *Fmr1* KO mice on C57Bl/6J background and the 129xBL6 background is complete. These crosses did not make the *Fmr1* phenotypes more prominent. We were able to complete all our behavioral studies using the C57Bl/6J background and found a new phenotype, which we will be reporting with manuscripts in preparation.

Task ???-Metformin treatment demonstrated mixed results. Treatment over a short period of time was able to rescue some phenotypes, but not others. Chronic treatment over an extended period of time through development was unable to rescue any phenotype. This suggests that a compensatory mechanism exists to limit the impact of metformin on the mTOR pathway, which diminishes enthusiasm for its possible use in treatment of behavioral deficits in Fragile X Syndrome.

Manuscripts in preparation:

Tudor, J.C., Wei, W., Davis, E.J., Chung, C.W., Abel, T., and Jongens, T. Metformin can rescue behavioral deficits in a mouse model of Fragile-X syndrome but not with chronic use.

Tudor, J.C., Davis, E.J., Jongens, T., and Abel, T. The *Fmr1* knockout mouse model behavior phenotype is fluid.

Completion of PDE4 studies in the *Drosophila* fragile X model. (items 2a, 4a and b, 5a, and 8a on Statement of Work.)

For Task 2a we have established several stocks to genetically validate the results that indicate that pharmacological inhibition of Gsk3beta activity can rescue Short-term memory, as well as to examine the impact of targeting downstream members of the mGluR signaling pathway. These stocks are currently being validated.

Task 4: In studies to examine the effects of PI3K antagonists on the *dfmr1* mutants we have found that the naïve courtship and short-term memory phenotypes can be rescued. These results have been validated genetically as shown below. Interestingly we have also been able to rescue the circadian defect displayed by the *dfmr1* mutants. The circadian phenotype however was not rescued by the pharmacological treatment. In experiments unrelated to this grant we have found that the critical period for decreasing PI3K activity with respect to circadian behavior is during the pupal period, a time in development that we cannot administer pharmacological agents, easily.




Figure 1| The short-term memory defect of *dfmr1* mutant flies is rescued by expression of *dfmr1* in the IPCs, genetic reduction of PI3K signaling activity. Graphs depict courtship indices of naïve males (black) and males trained with a mated female (white). **a**, Expression of *dfmr1* in the IPCs of *dfmr1* mutant flies restores memory, $p < 0.001$. Memory is not seen in *dfmr1* mutants carrying the *dilp2-Gal4* or *UAS-dfmr1* transgenes alone. **b**, STM is restored in *dfmr1* mutants heterozygous for a *dilp2* mutation, $p < 0.05$. **c**, STM is restored in *dfmr1* mutants expressing DP110^{DN} pan-neuronally, $P < 0.01$. **d**, STM is restored in *dfmr1* mutants over-expressing PTEN pan-neuronally, $P < 0.001$. All error bars depict s.e.m.




Figure 2| Genetic reduction of the insulin pathway rescues the circadian defect observed in *dfmr1* mutants. **a-d**, Panels show the percent rhythmic (black) and relative FFT values (white) for genetic combinations testing the effect of reducing insulin signaling in *dfmr1* mutants on circadian behavior. **a**, Circadian behavior of *dfmr1* mutants with the *WTrescue* transgene or with one copy of a null allele of *dilp2* (*dilp2*+/+, *dfmr1*⁻) display significantly improved circadian behavior relative to *dfmr1* mutants, $p < 0.001$. **b**, Circadian behavior of *dfmr1* mutants with the *WTrescue* transgene or with one copy of a mutant allele of the insulin receptor (*InR*+/+, *dfmr1*⁻) display significantly improved circadian rhythmic strength relative to *dfmr1* mutants, $p < 0.001$. **c**, Circadian behavior of *dfmr1* mutants with both *elav-Gal4* and *UAS-DP110^{DN}* (*elav*>*DP110^{DN}*, *dfmr1*⁻) display

significantly improved rhythmicity relative to *dfmr1* mutants with either transgene alone (*elav-Gal4*, *dfmr1*⁻) and (*UAS-DP110^{DN}*, *dfmr1*⁻), $p < 0.01$. **d**, Circadian behavior of *dfmr1* mutants with both *elav-Gal4* and *UAS-PTEN* (*elav*>*PTEN*, *dfmr1*⁻) display significantly improved circadian behavior relative to *dfmr1* mutants with either transgene alone (*elav-Gal4*, *dfmr1*⁻) and (*UAS-PTEN*, *dfmr1*⁻), $p < 0.001$ and $p < 0.05$ respectively. Significance denoted as described in Fig. 1. Error bars represent s.e.m.

Task 5: We have tested the effect of treating the *dfmr1* mutants with the Gsk-3beta inhibitor AR-A014418 during development and in adults. While we have not detected an effect on naïve courtship, we have found that treatment of *dfmr1* mutants during adulthood rescues the short-term memory deficit.




Figure 3. Treatment of the *dfmr1* mutants with the Gsk 3beta inhibitor AR-A014418 rescues short term memory. A) Both *dfmr1* mutants (FS) and controls (Rescue) display normal learning during training (Initial vs Final). The mutants however fail to display memory (reduced courtship) after the training. B) Treatment with AR-A014418 during adulthood rescues the short-term memory deficit (60 minutes) and has no negative effect on memory in the controls. C) Vehicle treatment for AR-A014418 has no effect on memory.

Task 12c. In testing the *dfmr1* mutants for behavioral phenotypes, we have found that few reported phenotypes could be reproduced in our hands using the BL6 genetic background. We have therefore initiated testing in a 129XB16 background and so far have found phenotypes to be more clear. We have now established conditions to perform the rotorod test that show a clear and reproducible difference between the mutants and littermate controls. We also have initial results that indicate the that object displacement assay is revealing a phenotype and the Y-maze is displaying a phenotype, however more n's need to be tested in these last two assays to determine if we can obtain statistically significant differences (not shown).





Figure 4| Treatment with metformin rescues memory in *dfmr1* mutants. Panels show the effect of metformin treatment on memory. **e**, STM is measured using memory index (MI) calculated from the courtship indices (CIs) of naïve (untrained) and trained flies using the formula $MI = (CI_{naïve} - CI_{trained}) / CI_{naïve}$. Error bars are not shown for memory indices. **e**, *dfmr1* mutants treated with metformin demonstrated STM, $p < .001$ in contrast to *dfmr1* mutants treated with vehicle alone which did not demonstrate memory. N ranges from 36-86. **f-h**, Flies were also tested using the classical olfactory conditioning memory paradigm. Performance index (PI) represents the percent of flies which avoid the shock-conditioned odor. **f**, Immediate olfactory conditioning memory, named learning, was significantly improved in *dfmr1* mutants after being administered a dose of metformin ($p < 0.0001$). No effect was observed in wild-type controls. N = 6 PIs per group. **g**, One day memory after spaced training is significantly improved in *dfmr1* mutant flies after being given a dose of metformin overnight before training. ($p < 0.00018$) N = 8 PIs per group. **h**, One day memory after massed training did not differ between groups. N = 8 PIs per group. Graph depicts mean $\pm$ s.e.m.

Reportable outcomes:

Key Research Accomplishments:

Task 2a-The outcrossing of *Gsk-3beta*, *IPPase*, *InsP3R*, *Rheb*, *S6K* mutant stocks and the transgenic stocks *UAS-AMPK*, *UAS-4EBP* is complete we are now in the process of initiating the behavioral testing with these stocks.

Task 4. Test PI3K antagonists on the *Drosophila* fragile X model.

4a. Test naïve courtship, learning during training (LDT), and memory (STM) in *dfmr1* mutant and control flies treated with drug or vehicle with continuous, development alone or adulthood alone.

4b. Genetically validate the results obtained with the PI3K inhibitors.

Task 5. Test Gsk-3Beta antagonists on the *Drosophila* fragile X model.

5a. Test naïve courtship, learning during training (LDT), and memory (STM) in *dfmr1* mutant and control flies treated with drug or vehicle with continuous, development alone or adulthood alone.

8a. Examine naïve courtship, learning during training and memory in *dfmr1* mutants and controls treated with metformin vehicle during development alone, adulthood alone and during both times.

Ongoing tasks:

Task 1c. Perform biochemical analysis to determine effects of PDE-4 inhibition on PI3K and Akt activity and smRP6 levels.

Using an elisa assay to quantitate cAMP levels, we have now established that the *dfmr1* mutants have reduced resting levels of cAMP. We have also determined that treatment with rolipram can rescue the deficit of cAMP. Therefore we are in a position to now examine the effect of PDE-4 inhibition on PI3K, Akt and smRP6 levels.

2b. Molecular and genetic validation of genetic stocks. The *InsP₃R*, *dfmr1* and *Rheb*, *dfmr1* stocks may take additional time as the genes are genetically close to *dfmr1* on the 3rd chromosome.

5b. Genetically validate the results obtained with the Gsk-3Beta inhibitors.

5c. Perform biochemical analysis to determine effects of Gsk-3Beta inhibition on PI3K and Akt activity and smRP6 levels.

8a. Examine naïve courtship, learning during training and memory in *dfmr1* mutants and controls treated with ALCAR and vehicle during development alone, adulthood alone and during both times.

12c. Perform behavioral testing battery on *FMRI* KO and control mice.

13c. Perform behavioral testing on *FMRI* KO and control mice that are treated with PDE- 4, PDE-8 inhibitors or vehicle.

Manuscripts Published:

1) Wolman MA, de Groh ED, McBride SM, Jongens TA, Granato M, and Epstein JA. Modulation of cAMP and ras signaling pathways improves distinct behavioral deficits in a zebrafish model of neurofibromatosis type 1. Cell Rep. 2014 Sep 11;8(5):1265-70. doi: 10.1016/j.celrep.2014.07.054. Epub 2014 Aug 28.

2) PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of Fragile X syndrome.

Choi C.H., Schoenfeld B.P., Bell A.J., Hinchey J., Choi R.J., Hinchey P., Kollaros M., Gertner M.J., Ferrick N.J., Terlizzi A.M., Yang Y., Woo N.H., Tranfaglia M.R., Siegel S.J., McDonald T.V., Jongens T.A., McBride S.M.J.. J. of Neuroscience 2015 Jan 7;35(1):396-408. doi: 10.1523/JNEUROSCI.1356-12.2015.

3) **Insulin signaling misregulation underlies circadian and cognitive deficits in a Drosophila fragile X model.** Monyak RE, Emerson D, Schoenfeld BP, Zheng X, Chambers DB, Rosenfelt C, Langer S, Hinchey P, Choi CH, McDonald TV, Bolduc FV, Sehgal A, McBride SM, Jongens TA. Mol Psychiatry. 2016 Apr 19. doi: 10.1038/mp.2016.51.

4) **Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.** Choi CH, Schoenfeld BP, Bell AJ, Hinchey J, Rosenfelt C, Gertner MJ, Campbell SR, Emerson D, Hinchey P, Kollaros M, Ferrick NJ, Chambers DB, Langer S, Sust S, Malik A, Terlizzi AM, Liebelt DA, Ferreira D, Sharma A, Koenigsberg E, Choi RJ, Louneva N, Arnold SE, Featherstone RE, Siegel SJ, Zukin RS, McDonald TV, Bolduc FV, Jongens TA, McBride SM. Front Behav Neurosci. 2016 Jun 30;10:136. doi: 10.3389/fnbeh.2016.00136. eCollection 2016.

Conclusions:

The overall objective of the work we have accomplished so far was to examine the efficacy of pharmacologically inhibiting PDE-4 activity to correct synaptic plasticity impairments in the fly and mouse models of Fragile X syndrome. The *Drosophila* Fragile X model recapitulates the most debilitating aspect of the disease in humans, namely impaired cognitive function. In our further dissection of the proteins involved in the mGluR signaling cascade, we identified PDE-4 as a potential substrate whose inhibition may be beneficial in restoring proper intracellular signaling in the Fragile X model (Fig. 1A). Based on the fly data, tissue culture work, the mouse model and samples from humans afflicted with Fragile X syndrome, we speculated that cAMP levels are suppressed (Berry-Kravis and Sklena, 1993; Berry-Kravis et al., 1995; Berry-Kravis and Ciurlionis, 1998; McBride et al., 2005; Kelley et al., 2007). PDE-4 inhibition should increase cAMP signaling by preventing the breakdown of cAMP that is produced during synaptic stimulation. Fragile X flies chronically treated in adulthood with PDE-4 inhibitors, or with genetically reduced levels of PDE-4, demonstrated intact immediate recall and short-term memory, validating PDE-4 inhibition as a potential novel therapeutic target for the treatment of synaptic plasticity impairments in Fragile X. We have validated the findings that indicate that cAMP levels are decreased in *dfmr1* mutants and that they are normalized by treatment with the drug rolipram. This finding adds to the growing body of literature demonstrating that pharmacologic treatment initiated in adulthood may have efficacy for the treatment of cognitive disorders that are already present in childhood as was first demonstrated in animal models of Fragile X and Neurofibromatosis type 1 in 2005 (Li et al., 2005; McBride et al., 2005; for review see Raymond and Tarpey, 2006; or Walsh et al., 2008).

In summary our work demonstrates that PDE-4 inhibition is a novel therapeutic target for the treatment of Fragile X. Prior to this work, it has only recently been demonstrated that enhanced LTD in the Fragile X model could be abrogated by chronic pharmacologic treatment (Choi et al., 2011). Equally as important is the demonstration that treatment in adulthood alone can rescue the phenotype, meaning that the phenotype is not irreversibly determined by pathogenic developmental circuitry. These findings urge the need for further exploration of PDE-4 inhibition as a potential therapy in Fragile X patients and in animal models of fragile X. Additionally, this work is a stepping stone for the field to begin a further pharmacologic dissection of the pathogenic signaling leading to aberrant LTD in the Fragile X model mouse, with the hope of these findings allowing the treatment of patients afflicted with Fragile X.

References:

- Akins MR, Berk-Rauch HE, Fallon JR (2009) Presynaptic translation: stepping out of the postsynaptic shadow. *Front Neural Circuits* 3:17.
- Bailey CP, Nicholls RE, Zhang XL, Zhou ZY, Muller W, Kandel ER, Stanton PK (2008) Galpha(i2) inhibition of adenylate cyclase regulates presynaptic activity and unmasks cGMP-dependent long-term depression at Schaffer collateral-CA1 hippocampal synapses. *Learn Mem* 15:261-270.
- Bakker CE, Oostra BA (2003) Understanding fragile X syndrome: insights from animal models. *Cytogenet Genome Res* 100:111-123.
- Banerjee P, Schoenfeld BP, Bell AJ, Choi CH, Bradley MP, Hinchey P, Kollaros M, Park JH, McBride SM, Dockendorff TC (2010) Short- and long-term memory are modulated by multiple isoforms of the fragile X mental retardation protein. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 30:6782-6792.
- Barad M, Bourtchouladze R, Winder DG, Golan H, Kandel E (1998) Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. *Proc Natl Acad Sci U S A* 95:15020-15025.
- Bear MF, Huber KM, Warren ST (2004) The mGluR theory of fragile X mental retardation. *Trends Neurosci* 27:370-377.
- Berry-Kravis E, Huttenlocher PR (1992) Cyclic AMP metabolism in fragile X syndrome. *Ann Neurol* 31:22-26.
- Berry-Kravis E, Sklena P (1993) Demonstration of abnormal cyclic AMP production in platelets from patients with fragile X syndrome. *Am J Med Genet* 45:81-87.
- Berry-Kravis E, Ciurlionis R (1998) Overexpression of fragile X gene (FMR-1) transcripts increases cAMP production in neural cells. *J Neurosci Res* 51:41-48.
- Berry-Kravis E, Hicar M, Ciurlionis R (1995) Reduced cyclic AMP production in fragile X syndrome: cytogenetic and molecular correlations. *Pediatr Res* 38:638-643.
- Berry-Kravis E, Sumis A, Hervey C, Nelson M, Porges SW, Weng N, Weiler IJ, Greenough WT (2008) Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. *J Dev Behav Pediatr* 29:293-302.
- Bhogal B, Jongens TA (2011) Fragile X syndrome and model organisms: identifying potential routes of therapeutic intervention. *Dis Model Mech*.
- Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM (2009) Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. *J Med Genet* 46:94-102.
- Bolduc FV, Bell K, Cox H, Broadie KS, Tully T (2008) Excess protein synthesis in *Drosophila* fragile X mutants impairs long-term memory. *Nat Neurosci* 11:1143-1145.
- Byers D, Davis RL, Kiger JA, Jr. (1981) Defect in cyclic AMP phosphodiesterase due to the dunce mutation of learning in *Drosophila melanogaster*. *Nature* 289:79-81.
- Choi CH, Schoenfeld BP, Bell AJ, Hinchey P, Kollaros M, Gertner MJ, Woo NH, Tranfaglia MR, Bear MF, Zukin RS, McDonald TV, Jongens TA, McBride SM (2011) Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment. *Brain research* 1380:106-119.
- Choi CH, McBride SM, Schoenfeld BP, Liebelt DA, Ferreira D, Ferrick NJ, Hinchey P, Kollaros M, Rudominer RL, Terlizzi AM, Koenigsberg E, Wang Y, Sumida A, Nguyen HT, Bell AJ, McDonald TV, Jongens TA (2010) Age-dependent cognitive impairment in a *Drosophila* fragile X model and its pharmacological rescue. *Biogerontology* 11:347-362.
- Choi Y, Kim HS, Shin KY, Kim EM, Kim M, Kim HS, Park CH, Jeong YH, Yoo J, Lee JP, Chang KA, Kim S, Suh YH (2007) Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's disease models. *Neuropsychopharmacology* 32:2393-2404.
- Cuello AC, Ferretti MT, Leon WC, Iulita MF, Melis T, Ducatenzeiler A, Bruno MA, Canneva F (2010) Early-stage inflammation and experimental therapy in transgenic models of the Alzheimer-like amyloid pathology. *Neurodegener Dis* 7:96-98.

- Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB (2011) FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. *Cell* 146:247-261.
- Davis RL, Kiger JA, Jr. (1981) Duncce mutants of *Drosophila melanogaster*: mutants defective in the cyclic AMP phosphodiesterase enzyme system. *J Cell Biol* 90:101-107.
- Davis RL, Takayasu H, Eberwine M, Myres J (1989) Cloning and characterization of mammalian homologs of the *Drosophila duncce+* gene. *Proc Natl Acad Sci U S A* 86:3604-3608.
- Dockendorff TC, Su HS, McBride SM, Yang Z, Choi CH, Siwicki KK, Sehgal A, Jongens TA (2002) *Drosophila* lacking *dfmr1* activity show defects in circadian output and fail to maintain courtship interest. *Neuron* 34:973-984.
- Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF (2007) Correction of fragile X syndrome in mice. *Neuron* 56:955-962.
- Dudai Y, Jan YN, Byers D, Quinn WG, Benzer S (1976) duncce, a mutant of *Drosophila* deficient in learning. *P Natl Acad Sci USA* 73:1684-1688.
- Dujardin F (1850) Memoire sur le systeme nerveux des insectes. *Ann. Sci. Nat. Zool.*
- Fang X, Yu SX, Lu Y, Bast RC, Jr., Woodgett JR, Mills GB (2000) Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. *Proc Natl Acad Sci U S A* 97:11960-11965.
- Garcia-Alloza M, Prada C, Lattarulo C, Fine S, Borrelli LA, Betensky R, Greenberg SM, Frosch MP, Bacsikai BJ (2009) Matrix metalloproteinase inhibition reduces oxidative stress associated with cerebral amyloid angiopathy in vivo in transgenic mice. *J Neurochem* 109:1636-1647.
- Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. *J Clin Invest* 114:1624-1634.
- Gross C, Berry-Kravis EM, Bassell GJ (2012) Therapeutic strategies in fragile X syndrome: dysregulated mGluR signaling and beyond. *Neuropsychopharmacology* 37:178-195.
- Hagerman PJ (2008) The fragile X prevalence paradox. *J Med Genet* 45:498-499.
- Hagerman R, Lauterborn J, Au J, Berry-Kravis E (2012) Fragile X syndrome and targeted treatment trials. Results and problems in cell differentiation 54:297-335.
- Henkel-Tigges J, Davis RL (1990) Rat homologs of the *Drosophila duncce* gene code for cyclic AMP phosphodiesterases sensitive to rolipram and RO 20-1724. *Mol Pharmacol* 37:7-10.
- Hou J, Kuromi H, Fukasawa Y, Ueno K, Sakai T, Kidokoro Y (2004) Repetitive exposures to nicotine induce a hyper-responsiveness via the cAMP/PKA/CREB signal pathway in *Drosophila*. *Journal of neurobiology* 60:249-261.
- Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E (2006) Dynamic translational and proteasomal regulation of fragile X mental retardation protein controls mGluR-dependent long-term depression. *Neuron* 51:441-454.
- Huber KM, Kayser MS, Bear MF (2000) Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. *Science* 288:1254-1257.
- Huber KM, Roder JC, Bear MF (2001) Chemical induction of mGluR5- and protein synthesis--dependent long-term depression in hippocampal area CA1. *J Neurophysiol* 86:321-325.
- Huber KM, Gallagher SM, Warren ST, Bear MF (2002) Altered synaptic plasticity in a mouse model of fragile X mental retardation. *Proc Natl Acad Sci U S A* 99:7746-7750.
- Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA (2007) Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. *Lancet Neurol* 6:45-55.
- Joiner ML A, Griffith LC (1997) CaM kinase II and visual input modulate memory formation in the neuronal circuit controlling courtship conditioning. *J Neurosci* 17:9384-9391.
- Kamyshev NG, Iliadi KG, Bragina JV (1999) *Drosophila* conditioned courtship: two ways of testing memory. *Learn Mem* 6:1-20.
- Kane NS, Robichon A, Dickinson JA, Greenspan RJ (1997) Learning without performance in PKC-deficient *Drosophila*. *Neuron* 18:307-314.
- Kelleher RJ, 3rd, Govindarajan A, Tonegawa S (2004) Translational regulatory mechanisms in persistent forms of synaptic plasticity. *Neuron* 44:59-73.

- Kelley DJ, Davidson RJ, Elliott JL, Lahvis GP, Yin JC, Bhattacharyya A (2007) The cyclic AMP cascade is altered in the fragile X nervous system. *PLoS ONE* 2:e931.
- Krueger DD, Bear MF (2011) Toward fulfilling the promise of molecular medicine in fragile X syndrome. *Annual review of medicine* 62:411-429.
- Li M, Wang X, Meintzer MK, Laessig T, Birnbaum MJ, Heidenreich KA (2000) Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3 β . *Mol Cell Biol* 20:9356-9363.
- Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ (2005) The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. *Curr Biol* 15:1961-1967.
- Liu ZH, Chuang DM, Smith CB (2011) Lithium ameliorates phenotypic deficits in a mouse model of fragile X syndrome. *Int J Neuropsychopharmacol* 14:618-630.
- Malenka RC, Bear MF (2004) LTP and LTD: an embarrassment of riches. *Neuron* 44:5-21.
- Martin-Chouly CA, Astier A, Jacob C, Pruniaux MP, Bertrand C, Lagente V (2004) Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors. *Life Sci* 75:823-840.
- McBride SM, Bell AJ, Jongens TA (2012) Behavior in a *Drosophila* model of fragile X. Results and problems in cell differentiation 54:83-117.
- McBride SM, Giuliani G, Choi C, Krause P, Correale D, Watson K, Baker G, Siwicki KK (1999) Mushroom body ablation impairs short-term memory and long-term memory of courtship conditioning in *Drosophila melanogaster*. *Neuron* 24:967-977.
- McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreira D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, McDonald TV, Jongens TA (2005) Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a *Drosophila* model of fragile X syndrome. *Neuron* 45:753-764.
- Michel CI, Kraft R, Restifo LL (2004) Defective neuronal development in the mushroom bodies of *Drosophila* fragile X mental retardation 1 mutants. *J Neurosci* 24:5798-5809.
- Min WW, Yuskaitis CJ, Yan Q, Sikorski C, Chen S, Jope RS, Bauchwitz RP (2009) Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential. *Neuropharmacology* 56:463-472.
- Mines MA, Jope RS (2011) Glycogen synthase kinase-3: a promising therapeutic target for fragile x syndrome. *Frontiers in molecular neuroscience* 4:35.
- Mines MA, Yuskaitis CJ, King MK, Beurel E, Jope RS (2010) GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism. *PLoS ONE* 5:e9706.
- Morales J, Hiesinger PR, Schroeder AJ, Kume K, Verstreken P, Jackson FR, Nelson DL, Hassan BA (2002) *Drosophila* fragile X protein, DFXR, regulates neuronal morphology and function in the brain. *Neuron* 34:961-972.
- Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH (2009) Minocycline reduces the development of abnormal tau species in models of Alzheimer's disease. *FASEB J* 23:739-750.
- Nosyreva ED, Huber KM (2006) Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. *J Neurophysiol* 95:3291-3295.
- O'Kane CJ (2011) *Drosophila* as a model organism for the study of neuropsychiatric disorders. *Current topics in behavioral neurosciences* 7:37-60.
- Oger S, Mehats C, Dallot E, Cabrol D, Leroy MJ (2005) Evidence for a role of phosphodiesterase 4 in lipopolysaccharide-stimulated prostaglandin E2 production and matrix metalloproteinase-9 activity in human amniochorionic membranes. *J Immunol* 174:8082-8089.
- Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW (2010) Open-label add-on treatment trial of minocycline in fragile X syndrome. *BMC neurology* 10:91.
- Pascual A, Preat T (2001) Localization of long-term memory within the *Drosophila* mushroom body. *Science* 294:1115-1117.
- Raymond FL, Tarpey P (2006) The genetics of mental retardation. *Hum Mol Genet* 15 Spec No 2:R110-116.

- Sanchez AJ, Puerta C, Ballester S, Gonzalez P, Arriaga A, Garcia-Merino A (2005) Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis. *J Neuroimmunol* 168:13-20.
- Santschi LA, Zhang XL, Stanton PK (2006) Activation of receptors negatively coupled to adenylate cyclase is required for induction of long-term synaptic depression at Schaffer collateral-CA1 synapses. *J Neurobiol* 66:205-219.
- Sato T, Tanaka K, Ohnishi Y, Teramoto T, Irifune M, Nishikawa T (2004) Inhibitory effects of group II mGluR-related drugs on memory performance in mice. *Physiol Behav* 80:747-758.
- Siegel RW, Hall JC (1979) Conditioned responses in courtship behavior of normal and mutant *Drosophila*. *Proc Natl Acad Sci U S A* 76:3430-3434.
- Spencer CM, Serysheva E, Yuva-Paylor LA, Oostra BA, Nelson DL, Paylor R (2006) Exaggerated behavioral phenotypes in *Fmr1/Fxr2* double knockout mice reveal a functional genetic interaction between Fragile X-related proteins. *Hum Mol Genet* 15:1984-1994.
- Tanji C, Yamamoto H, Yorioka N, Kohno N, Kikuchi K, Kikuchi A (2002) A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3beta (GSK-3beta) and mediates protein kinase A-dependent inhibition of GSK-3beta. *J Biol Chem* 277:36955-36961.
- Tessier CR, Broadie K (2012) Molecular and genetic analysis of the *Drosophila* model of fragile X syndrome. *Results and problems in cell differentiation* 54:119-156.
- Walsh CA, Morrow EM, Rubenstein JL (2008) Autism and brain development. *Cell* 135:396-400.
- Wang LW, Berry-Kravis E, Hagerman RJ (2010) Fragile X: leading the way for targeted treatments in autism. *Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics* 7:264-274.
- Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP (2005) Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. *Neuropharmacology* 49:1053-1066.
- Yuskaitis CJ, Beurel E, Jope RS (2010a) Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. *Biochim Biophys Acta* 1802:1006-1012.
- Yuskaitis CJ, Mines MA, King MK, Sweatt JD, Miller CA, Jope RS (2010b) Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome. *Biochem Pharmacol* 79:632-646.
- Zars T, Fischer M, Schulz R, Heisenberg M (2000) Localization of a short-term memory in *Drosophila*. *Science* 288:672-675.
- Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, Rubin GM, Broadie K (2001) *Drosophila* fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. *Cell* 107:591-603.